Advertisement
Advertisement
U.S. markets open in 5 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Huize Holding Limited (HUIZ)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8500+0.0160 (+1.92%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close0.8340
Open0.8000
Bid0.0000 x 1100
Ask0.0000 x 4000
Day's Range0.7900 - 0.9006
52 Week Range0.6100 - 7.1900
Volume19,968
Avg. Volume263,015
Market Cap44.062M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateMay 16, 2022 - May 20, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.49
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HUIZ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Huize Holding Limited
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, la ong-acting recombinant human growth hormone (rhGH); lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Simply Wall St.

    Huize Holding Limited (NASDAQ:HUIZ): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse Huize Holding Limited's ( NASDAQ:HUIZ ) business as it appears the company...

  • GlobeNewswire

    Huize Provides Update on its Status under the Holding Foreign Companies Accountable Act

    SHENZHEN, China, May 05, 2022 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize,” the “Company” or “we”) (NASDAQ: HUIZ), a leading digital insurance product and service platform for new generation consumers in China, today announced that the Company is aware of the fact that it was identified by the United States Securities and Exchange Commission (the “SEC”) under the Holding Foreign Companies Accountable Act of the United States (the “HFCAA”) on May 4, 2022. Such identification may have resul

  • GlobeNewswire

    Huize Holding Limited Files 2021 Annual Report on Form 20-F

    SHENZHEN, China, April 27, 2022 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize,” the “Company” or “we”) (NASDAQ: HUIZ), a leading digital insurance product and service platform for new generation consumers in China, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (the “SEC”) on April 27, 2022. The annual report can be accessed on the SEC’s website at www.sec.gov and on the Company’s

Advertisement
Advertisement